Metabolic Impact on Offspring Similar for Frozen, Fresh Embryo Transfer
By Elana Gotkine HealthDay Reporter
FRIDAY, June 7, 2024 -- For glucose and lipid profiles during early childhood, the impact of frozen embryo transfer (FET) is comparable to that of fresh embryo transfer, according to a study published online June 6 in PLOS Medicine.
Wei Zhou, from Shandong University in Jinan, China, and colleagues compared the metabolic profiles of children born after frozen versus fresh embryo transfer at 2 to 5 years of age in a prospective cohort study. A total of 4,246 singletons born after FET and fresh embryo transfer (2,181 and 2,065, respectively) enrolled between 2008 and 2019 were included; glucose and lipid variables were examined until the age of 2 to 5 years.
The researchers found that in the crude and adjusted models, there were no significant differences in fasting blood glucose, fasting insulin, homeostatic model assessment of insulin resistance index, total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels between offspring conceived by fresh and frozen embryo transfer. Across subgroup analyses considering offspring age, the stage of embryo transfer, and the mode of fertilization, these results remained consistent.
"Compared to offspring born after fresh embryo transfer, those born after FET showed no significant adverse metabolic changes during early childhood in our large sample size study," the authors write. "However, the long-term metabolic health of offspring conceived through FET remains a concern, and continuous monitoring of their long-term metabolic health is necessary."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.